Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1128441

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of evidence base on the cost-effectiveness of medical cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257705
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:23:02 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1128442

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257706
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:18:03 question first ministerially corrected 11/06/2019 11:31:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 121340 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1128296

	registered interest
	date	22/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which countries his Department is engaging with in order to learn from their experiences in getting patients access to medical cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257472
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>In developing its policy on cannabis-based products for medicinal use, the Government looked at approaches taken by other countries to learn from their experience. Broadly two approaches have been taken: to regulate as a medicine (both licenced and unlicensed) as in the United Kingdom or to regulate outside of the medicinal regime as in Canada. In reviewing the available international evidence, the Chief Medical Officer for England and Chief Medical Adviser to the UK Government, looked at evidence reviews from the United States, Ireland, Australia, and the World Health Organization. Departmental officials have also reviewed information from a wide range of other countries and have spoken to the authorities and organisations in Australia, Canada, Denmark, the Netherlands, and the United States (New York).</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257473 question first answered 10/06/2019 13:28:33 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1128297

	registered interest
	date	22/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what evidence his Department has reviewed from other countries on the effectiveness of cannabis as a medicine.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257473
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>In developing its policy on cannabis-based products for medicinal use, the Government looked at approaches taken by other countries to learn from their experience. Broadly two approaches have been taken: to regulate as a medicine (both licenced and unlicensed) as in the United Kingdom or to regulate outside of the medicinal regime as in Canada. In reviewing the available international evidence, the Chief Medical Officer for England and Chief Medical Adviser to the UK Government, looked at evidence reviews from the United States, Ireland, Australia, and the World Health Organization. Departmental officials have also reviewed information from a wide range of other countries and have spoken to the authorities and organisations in Australia, Canada, Denmark, the Netherlands, and the United States (New York).</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257472 question first answered 10/06/2019 13:28:33 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1128299

	registered interest
	date	22/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care on 20 May 2019, Official Report, column, 571, what plans he has to include observational trials in building up the existing evidence-base.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257475
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>In all areas of scientific research, a range of evidence builds our understanding. This includes individual cases and observational trials. It is the promise shown from these observational studies and experience, from all around the world, that provides the basis for public funding of further research into the use of cannabis based products as medicines through the National Institute for Health Research. This further clinical research will provide a greater level of understanding of cannabis-based medicines, how to use them to best effect, who may benefit and under what circumstances, how cannabis interacts with other medications and define further any contraindications. It is this level of research outcomes that will provide confidence to prescribers and the information necessary to make routine funding decisions within the National Health Service.</p><p>The existing experience, studies and research in this area will be used by the National Institute for Health and Care Excellence to develop their clinical guidelines due to be published later this year.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:26:43 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1128300

	registered interest
	date	22/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the cost-effectiveness of patients receiving an NHS prescription for wholeplant medical cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257476
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257706 question first answered 10/06/2019 13:18:03 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning